XYCROBE THERAPEUTICS - Key Persons

Job Titles:

• Kauffman Fellow
• Principal at Greenspring Associates

Adair Newhall is a Principal at Greenspring Associates and is responsible for sourcing and due diligence efforts on fund, direct and secondary opportunities. Mr. Newhall currently serves on the Bright Health and Crown Laboratories Boards and as an Observer on the Paladina Health Board. Mr. Newhall previously served as a Principal at Domain Associates, a leading healthcare-focused venture captial firm, and Greenspring Associates fund manager. At Domain Associates, he held board observer positions with several portfolio companies, including Applied Proteomics, Astute Medical, BioNano Genomics, CoLucid Pharmaceuticals and Xagenic. He was previously involved as a board observer with Otonomy (NASDAQ: OTIC), which completed a successful initial public offering in August 2014. Prior to joining Domain Associates in August 2009, Mr. Newhall worked in the Business Development group at Esprit Pharma, where he assisted with multiple product acquisitions and the subsequent sale of the company to Allergan (NYSE: AGN) for $370 million. Before that, he worked at ESP Pharma, which was acquired by PDL BioPharma (NASDAQ: PDLI) for $514 million. He received his M.B.A from the Darden Graduate School of Business Administration at the University of Virginia and his undergraduate degree from the University of Pennsylvania. Currently, Mr. Newhall is a Kauffman Fellow and a co-founder of the UVa Venture Summit.

Job Titles:

• General Manager, Crown Premium Skincare

Alison Yeh has served as StriVectin's Chief Marketing Officer since 2016, leading the Global Brand Marketing, Product Development & Regulatory Affairs teams for the company. She joined StriVectin Operating Company, Inc. from Alterna Haircare (Henkel Beauty), where she spent nearly five years, culminating in an international assignment as the Asia Pacific Regional Manager, based in Singapore. She has spent 15+ years in the beauty and personal care industry, with additional brand leadership roles at Johnson & Johnson, Elizabeth Arden and Frédéric Fekkai. She holds an MBA from Northwestern University's Kellogg School of Management and a BSBA from Georgetown University's McDonough School of Business.

Job Titles:

• Founder of Vita Liberata

Alyson Hogg is the Founder and Creator of Vita Liberata. Ms. Hogg has enjoyed a multi-faceted professional career, which has spanned broadcasting, academia, hospitality and politics. She was Communications Director of the Women's Coalition in Northern Ireland during the 1998 Peace Process, before creating Vita Liberata in 2003. Ms. Hogg has been the inspiration behind the Vita Liberata brand's phenomenal success. She joined Crown Laboratories in 2017 and has been a Director since 2018. Ms. Hogg completed her undergraduate studies in Philosophy and was researching her Ph.D. in Philosophy of Psychology, when she decided to focus on business instead. She holds the position of Distinguished Graduate at the University of Ulster and received the Queen's Award for Industry in 2014 and 2015. She was awarded the MBE (Member of the Order of the British Empire) in the Queen's Honours List in 2017.

Job Titles:

• Chief Commercial Officer
• President
• President and Chief Commercial Officer of Crown Laboratories, Inc

Cori Aleardi is the President and Chief Commercial Officer of Crown Laboratories, Inc. Before Crown, Ms. Aleardi was President of StriVectin Operating Company, Inc., and formerly held the roles of Chief Operating Officer and Chief Financial Officer. Prior to joining StriVectin, Ms. Aleardi was a Vice President at L Catterton, the largest global consumer-focused private equity firm, where she led transactions and worked across many portfolio companies on a range of strategic efforts. Ms. Aleardi joined L Catterton from Kraft Foods, where she served in various brand management roles across the company's iconic brands. Ms. Aleardi also worked for Parthenon Capital, a middle-market PE fund, J.P. Morgan, and the Beacon Group, a boutique advisory and PE firm. Ms. Aleardi received her MBA with high distinction from Harvard Business School and holds an AB cum laude in economics from Harvard College.

Job Titles:

• General Partner and Managing Member of Montreux Equity Partners

Dan Turner has 30 years of experience as an entrepreneur, operating manager and investor. He founded Montreux Equity Partners and has been a General Partner and Managing Member with Montreux since 1993. Mr. Turner has invested in companies across consumer, healthcare services, pharmaceuticals and technology sectors. Some of his previous investments include Paymap (acquired by First Data Corp), Peapod (IPO; acquired by Royal Ahold), and Great Lakes Health Plan (acquired by United Healthcare). Mr. Turner is a member of the Board of Directors of Avantis Medical, GC Aesthetics, Moksha8, Pure Life Renal, KNOW Foods, and Crown Laboratories, Inc. He is a member of the Advisory Board of the Lester Center, located at the Haas School of Business, University of California, Berkeley. Mr. Turner previously served as Montreux's representative to the Board of Directors of Glaukos (NYSE: GKOS), Tobira Therapeutics, Epirus Biopharmaceuticals (NASDAQ: EPRS), Renal CarePartners (sold to Ambulatory Services of America in 2011), Cerexa (sold to Forest Laboratories in 2007), NovaCardia (sold to Merck in 2007), and Peninsula Pharmaceuticals (sold to Johnson & Johnson in 2005). Mr. Turner started his career with Price Waterhouse in the high technology group. He later became the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Prior to founding Montreux Equity Partners, Mr. Turner was a Principal in the Turnaround Group for Berkeley International. Mr. Turner holds a B.S. from California State University, Sacramento and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant.

Job Titles:

• Chairman of the Board and Partner at Hildred Capital Partners

David F. Solomon is a Partner at Hildred Capital Partners. In association with Hildred's investments, Mr. Solomon currently serves as Chairman of the Board for Crown Laboratories. He serves on the Board of Quantum-Si, an innovative life sciences company; he is an Executive Partner at Tyree & D'Angelo, an investment firm focused on acquiring and consolidating individual operating healthcare-related businesses; and he is a member of the Shareholder's Council for Columbia Care, the leading medical marijuana business in the U.S. Prior to Hildred, Mr. Solomon served on the Board of Directors for Moksha8, a Latin American pharmaceutical company with commercial operations in Mexico and Brazil, and on the Board of Directors of Trevena, a public clinical stage biotech company, working in the area of G protein coupled receptor targeted medicines. Prior to launching Hildred Capital Partners, Mr. Solomon spent 14 years at Forest Laboratories, ultimately as Senior Vice President, Corporate Development & Strategic Planning. In that capacity, Mr. Solomon was responsible for Forest's Business Development activities, including all M&A, licensing and product acquisitions. He also had responsibility for Forest's Alliance Management group, which managed Forest's many collaborations, and its Strategic Planning functions, which focused on the review and evaluation of novel business opportunities, as well as life-cycle planning for Forest's portfolio. In addition, Mr. Solomon managed Forest's business outside the United States, including its European, Canadian and Latin American operations. He was also responsible for all of the company's Operations, including Manufacturing and Distribution, as well as its Informatics, Compliance and Quality Affairs functions. Mr. Solomon departed Forest, after the company was acquired by Actavis for approximately $28 billion in July 2014. Prior to joining Forest, Mr. Solomon practiced entertainment law at Paul Weiss Rifkind Wharton & Garrison in New York. Following that, he worked as Director of Creative Affairs at Paramount Pictures in Los Angeles, overseeing development and production of feature films for the studio and as an independent producer with Davis Entertainment, based at 20th Century Fox. Mr. Solomon has also produced the Peabody Award winning documentary film Rebirth, about a group of people whose lives were dramatically impacted by September 11th, which premiered at the Sundance Film Festival in January 2011. Mr. Solomon serves on the Board of Directors of Lincoln Center Theater and the Municipal Art Society and on the Executive Board of the Yale Dramat Alumni Association. Mr. Solomon has also served as a member of the Yale University Council Committee on Theater at Yale. Mr. Solomon graduated summa cum laude with a B.S. in Biology from Yale College, where he was elected to Phi Beta Kappa and received the Jonathan Edwards Fellows Prize for Academic Achievement and the Henry E. Ellsworth Prize for the most significant senior thesis in the Natural Sciences. He received his J.D. from Yale Law School, where he was a Coker Fellow and a Senior Editor of the Yale Law Journal.

Job Titles:

• Chief Science Officer
• Chief Science Officer for Crown Laboratories

Dr. Thomas Hitchcock serves as the Chief Science Officer for Crown Laboratories and oversees Clinical Development, Medical Affairs and Research & Development for Crown and its subsidiaries. He was also the Founder of Xycrobe Therapeutics Inc. and served as its Chief Executive Officer until acquired by Crown in 2019. Additionally, he was the Acting Chief Scientific Officer overseeing Clinical & Medical Affairs at Bellus Medical from its inception in 2013 up to the acquisition by Crown Laboratories. Dr. Hitchcock also currently serves as an adjunct faculty member of the East Tennessee State University Department of Biomedical Science. Previous to his work in the industry, Dr. Hitchcock performed research at Weill Cornell Medical College, where he studied multiple myeloma genetics. He also performed post-doctoral research in tissue engineering and regenerative medicine at Duke University and Yale University. Following his post-doctoral studies, Dr. Hitchcock began working in the field of dermatology at emerging companies such as Ulthera, Inc. (acquired by Merz in 2014), as well as consultancy for companies such as Boehringer Ingelheim and Bayer. Dr. Hitchcock has more than 15 years of research experience, including Basic Science, Proof-of-Concept, Pre-Clinical and Clinical Research across several therapeutic areas such as Cardiology, Oncology, Gene Therapy, Plastic/Facial Plastic Surgery, Dermatology and Aesthetic Medicine. Dr. Hitchcock earned his Ph.D. in Genetics from Clemson University and completed post-doctoral trainings at Duke University and Yale University in Biomedical Engineering, Vascular Biology and Therapeutics.

Job Titles:

• Chief Digital Officer
• Chief Digital Officer of StriVectin

Felicity Sissener has been the Chief Digital Officer of StriVectin since 2017 running the Direct to Consumer channel with a key focus on crafting and evolving the global digital/eCommerce strategy, performance marketing and technology roadmap. Prior to joining StriVectin, Felicity was Senior Vice-President, Marketing and eCommerce at Ippolita, an Italian luxury jewelry brand where she reshaped the overall marketing/digital strategy while rapidly growing eCommerce revenue and profitability. Throughout her career, Felicity has led eCommerce and CRM initiatives, directed advertising and communication efforts, consulted for retail industry leaders, and provided Digital/eCommerce transaction advisory services for Private Equity and post-acquisition digital transformation projects for global retail brands. Felicity received her Bachelor of Arts with Honors from Wellesley College.

Job Titles:

• Chief Operations Officer

Jack Songster was named COO for Crown Laboratories, Inc. in October 2014 and has been a Board Member of Crown Laboratories, Inc. since 2014. He joined Crown Laboratories in February 2012, assuming responsibility for all operations activities, and served as the Vice President of Manufacturing and Site GM at Crown Laboratories' facility in Johnson City, TN. Previously, Mr. Songster was Senior Vice President of Manufacturing for Pfizer, Inc. and King Pharmaceuticals, where he held multi-site technical operations responsibility for two solid-dosage and semi-solids plants, a sterile manufacturing site and a chromatographic purification location. Mr. Songster's wealth of manufacturing and logistics experience in the highly regulated medical device and pharmaceutical industry totals more than 25 years.

Job Titles:

• Chief Executive Officer
• President
• Director of Crown Laboratories, Inc
• President and Chief Executive Officer of Crown Laboratories, Inc

Jeff Bedard is the President and Chief Executive Officer of Crown Laboratories, Inc. Before founding Crown Laboratories, Inc. in 2000, Mr. Bedard held positions in sales and market development with Stiefel Laboratories, Inc. and Herald Pharmacal, Inc. Mr. Bedard owned a consulting firm, providing marketing and business development management advice for small to medium pharmaceutical companies. Mr. Bedard has been a Director of Crown Laboratories, Inc. since 2000 and served previously as Chairman of the Board and President. Mr. Bedard currently serves on the Boards of the ETSU Foundation and the Ballad Health Foundation. He recently was inducted into the Science Hill Sports Hall of Fame. Mr. Bedard graduated with honors from the University of Iowa with a degree in Chemistry.

Job Titles:

• General Manager of Crown Aesthetics

Joe Proctor is the General Manager of Crown Aesthetics and is an award-winning inventor in aesthetics. He launched Bellus Medical in 2012 to help leading physician-directed practices around the world grow their businesses. Acquired by Crown Laboratories in 2018, Bellus Medical (now Crown Aesthetics) specializes in non-invasive innovations that act as "gateway" products drawing new patients to its practice partners. Mr. Proctor began his career in aesthetics more than 18 years ago through progressive sales development and training. As a strong influencer in the industry, he leads by example by offering products of the highest quality and safety standards, and by providing best-in-class customer service and education. Joe was named as Non-Physician Technology Innovator of the Year from The Aesthetic Show. Crown Aesthetics has been the winner of multiple Aesthetic Everything Awards and the SkinPen® device won the United Kingdom-based Barry Knapp Award for Product Innovation of the Year.

Job Titles:

• Chief Financial Officer

Job Titles:

• Chief Accounting Officer

Mr. Crowe serves as Crown Laboratories' Chief Accounting Officer. Prior to joining Crown, Mr. Crowe was the senior manager of the Consulting and Audit Departments at a regional accounting firm, Blackburn, Childers and Steagall, PLC. While in public practice, Mr. Crowe specialized in manufacturing clients and medical practices. Mr. Crowe earned his bachelor's degree in Business Administration with concentrations in both Accounting and Logistics and Transportation from the University of Tennessee.

Job Titles:

• Vice President of Global Human Resources

Mr. Webb joined Crown in 2018 and is an experienced strategic business leader with more than 25 years of experience of full-scope Human Resources responsibilities. With a demonstrated history in executive leadership with multi-national responsibilities, Mr. Webb brings people-focus and high business acumen to the organization. Mr. Webb is skilled in executive coaching, employee engagement, change management, organizational design, HR development, facilitation, project management, HR compliance and strategic development. Mr. Webb has tremendous experience developing and implementing strategic and scalable business plans and solutions for growth-oriented businesses. Mr. Webb obtained his MBA from Western Carolina University.

Job Titles:

• Chief Creative Officer
• Chief Creative Officer of StriVectin Operating Company

Robert Squeri has been the Chief Creative Officer of StriVectin Operating Company since 2016. He is a keen strategic creative thinker who embodies the belief that "good design is good business." His creative expertise led to the transformation of numerous global beauty/personal care leaders including John Frieda, Jergens, Biore, Curel, and Lancome. He has had a career of record success within the retail and fashion industries from his work with Bloomingdales and Joseph Abboud Apparel as well. Robert has an innate ability to develop a brand's unique genetic code and bring it to life through visual and written execution. His innovative strategies keep brands relevant, growing and on-track for building long-term creative equity.

Job Titles:

• Managing Director at Hildred Capital Management
• Managing Director at Hildred Capital Partners

Stephen Hallenbeck is a Managing Director at Hildred Capital Management. He previously served as the Director of Private Equity at Hildred Capital Partners, where he was responsible for sourcing, evaluating, executing and managing investment opportunities within the Hildred private equity portfolio. Since joining HCP in 2016, Mr. Hallenbeck led six majority buyout acquisitions, arranging total debt and equity financings in aggregate of $450 million. In connection with his oversight at Hildred, Mr. Hallenbeck serves on the Board of Directors for Project Natural, a leading supplier of natural therapeutic consumer healthcare products; DermCare, a dermatology practice management company; SportsMed, a physical therapy practice management company; and Crown Laboratories, a premier dermatology, aesthetic and skincare product business. In addition to his role at HCM, Mr. Hallenbeck serves on the Board of Directors and Financial Sustainability Committee of the Triangle Fund, a community and youth-focused non-profit organization based in upstate New York. Prior to joining Hildred, Mr. Hallenbeck worked at Deutsche Bank Securities from 2009 to 2016, where he most recently worked in the Financial Sponsors Group. In this role, Mr. Hallenbeck identified and evaluated leveraged acquisitions and capital markets financings for both prospective and current portfolio companies of private equity firms. Prior to his time in the Financial Sponsors Group, Mr. Hallenbeck spent time as a member of Deutsche Bank's Healthcare Investment Banking team, focusing on M&A, debt and equity transactions for both private and public companies within the sector. Mr. Hallenbeck received a B.A. in Economics with honors from Vanderbilt University.

Job Titles:

• General Manager, Crown Therapeutics

Mr. Gallopo joined Crown in 2019 to lead the OTC Consumer business. Mr. Gallopo brings a vision of building and reestablishing brands through product innovation and retail channel expansion. Mr. Gallopo's experience ranges across all aspects of dermatology sales and marketing including OTC, medical device, aesthetics, and Rx. Mr. Gallopo has worked for several significant players in the space including Merz, GSK, and Stiefel. His track record includes the establishment of numerous #1 OTC and Rx brands as well as the development and execution of customer loyalty programs. Mr. Gallopo obtained his Bachelor of Science & Business Administration degree from Villanova University.

Job Titles:

• Customer Service

Job Titles:

• Managing Director at Hildred Capital Management

Wael Fayad has over 25 years of experience in the life sciences industry. He served as head of business development at Forest Laboratories Inc. and was a member of the leadership team that built Forest into a leading U.S. pharma company which was acquired for $28 billion. Prior to Forest, Mr. Fayad served at Novartis and Schering-Plough in various commercial and strategy roles. After leaving Forest, he worked with a number of smaller biotech and healthcare-oriented companies, including Enumeral Biomedical, where he served as Chairman and CEO, and ACCOY pharmaceuticals, where he co-founded the company and serves on its strategic advisory board. Mr. Fayad holds a bachelor's degree in Biology from the American University of Beirut and a Masters of Business Administration degree from Concordia University in Montreal, Canada.

Job Titles:

• Partner at Hildred Capital Partners

William Meury currently serves on the Board of Directors for Crown Laboratories. Mr. Meury served as the Chief Commercial Officer for Allergan from 2015-2020 where he had total P&L responsibility for over 50 products with $16B in revenue and over $3B in sales and marketing investment. He led multiple divisions consisting of 8,000 people around the world, including marketing, sales, business analytics, marketing operations, managed care, pricing, and customer service. Previously, Mr. Meury served as President, Branded Pharmaceuticals for Actavis, and Executive Vice President, Sales and Marketing, Forest Laboratories, Inc. Mr. Meury led three large commercial integrations, including the $28B merger between Forest & Actavis, the $66B merger between Actavis & Allergan, and the $63B merger between Allergan & Abbvie. Mr. Meury has over 25 years of experience in biopharmaceuticals and was directly responsible for over 20 new product launches across 10 therapeutic areas during his career. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. Mr. Meury serves on the Board of Directors for Syndax, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. He also serves on the Board of Directors for the Jed Foundation, a non-profit organization that protects emotional health and prevents suicide for teens and young adults in the United States. Mr. Meury has a B.A. in Economics from the University of Maryland.